What is included in the long-term monitoring of patients with persistent depressive disorder (dysthymia)?

Updated: Oct 01, 2019
  • Author: Jerry L Halverson, MD; Chief Editor: David Bienenfeld, MD  more...
  • Print

Because of the high rate of relapses from depression and from dysthymia, follow-up is important.

The patient who has recovered with pharmacotherapy should be encouraged to continue follow-up for at least 6 months before considering any medication taper.

Because of the chronic nature of dysthymia, long-term treatment with medications is often advisable. In cases where a medication loses its effectiveness, a new regimen should be considered.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!